Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Forestviewon Mar 22, 2024 12:47pm
474 Views
Post# 35947445

Update

UpdateHey, so going to jump in since there's alot of speculation.  And given that Duster is trying to drive down SP by spewing nonsense (again), I'll share some takeaways from a call I had with Dan.  He takes calls, Duster.  Why don't you actually call him?

Some highlights:
- P2 is still happening on target, and funds are available
- ATE isn't going bankrupt, nor looking to dilute. Plan is to NEGOTIATE with Nuance.  Those discussions have been happening over the last few weeks.  There will be an announcement when there is something to announce.
- It's in Nuance's best interest to let P2 play out.  There is no money to pay them if P2 doesn't happen.  Nuance is just a creditor.  So, company goes bankrupt, there goes their chance to get their money.  So, letting P2 happen is in THEIR BEST INTEREST.  This may mean Nuance gets more than the penalty awarded, but a successful P2 will mean it's a drop in the bucket anyway.  And, reiterating, it's in Nuance's best interest to let P2 happen.
- The goal is to start P2.  
- Nothing can be shared until it's final.  Things are happening in the background.

Honestly, call Dan himself.  He'll take the call.  Yes, he's working insane hours, no he doesn't want to keep doing it, but the goal remains to License Otena, and P2 is the process to get there.

Hope this helps.  And a friendly reminder that Duster is ATE's biggest fan when he owns shares, and it's biggest enemy when he doesn't.  It's easy to see when he does.

Have a good weekend longs.  
<< Previous
Bullboard Posts
Next >>